Form 4: Amneal Pharmaceuticals Executive Vice President Tasos Konidaris Reports Changes in Beneficial Ownership

Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports transactions involving Class A Common Stock and Restricted Stock Units.

Summary

• Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
• The transactions involve Class A Common Stock and Restricted Stock Units (RSUs).
• On March 1, 2024, 36,197 shares were acquired through vesting of RSUs, with 13,257 shares withheld for tax obligations at a price of $5.47.
• On March 3, 2024, additional shares were acquired through vesting of RSUs: 45,290 and 57,339 shares, with 15,897 and 20,126 shares withheld for tax obligations at a price of $5.47.
• On March 4, 2024, 175,926 Restricted Stock Units and 351,852 Performance-Based Restricted Stock Units were granted.
• The reporting person directly owns 470,386 shares of Class A Common Stock following the reported transactions.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider transactions, suggesting a neutral to slightly positive sentiment as it indicates continued alignment of management with shareholder interests.

Positives

• The reporting person increased their direct ownership of Class A Common Stock to 470,386 shares.
• The grant of 175,926 Restricted Stock Units and 351,852 Performance-Based Restricted Stock Units indicates continued alignment with the company's long-term performance.

Negatives

• Shares were withheld to cover tax obligations, reducing the net increase in shares held.

Risks

• The value of the performance-based restricted stock units is contingent on the company's Class A Common Stock achieving certain average closing price targets, which may not be met.
• The number of shares received upon vesting of performance-based restricted stock units may vary from 0% to 200% of the target number.

Future Outlook

The restricted stock units vest in four equal annual installments beginning on March 4, 2025. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period ending February 28, 2027.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the alignment of management's interests with those of shareholders. The vesting of RSUs and grants of new equity-based compensation are common practices in the pharmaceutical industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Equity compensation practices, including the use of restricted stock units and performance-based units, are common among publicly traded pharmaceutical companies such as Teva Pharmaceutical Industries, Mylan (now Viatris), and Perrigo.
• The vesting schedules and performance metrics associated with these grants are typically designed to align with long-term shareholder value creation.
• The specific terms of Amneal's equity grants, such as the vesting schedule and performance targets, would need to be compared to those of its peers to assess their relative competitiveness and effectiveness.

Stakeholder Impact

• Shareholders may view the increased equity ownership of the CFO positively, as it aligns his interests with the company's performance.
• Employees may see the equity grants as a positive sign of the company's commitment to its leadership team.

Next Steps

• The restricted stock units will continue to vest in future periods.
• The performance-based restricted stock units will vest based on the company's stock performance through February 28, 2027.

Key Dates